Compare Fidelity National Information Servcs Inc (FIS) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Heron Therapeutics Inc — how do they compare? Fidelity National Information Servcs Inc trades at $42.08 (market cap $21.24B), while Heron Therapeutics Inc trades at $0.48 (market cap $84.50M). The key difference: Fidelity National Information Servcs Inc is far larger — about 251.4× Heron Therapeutics Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.09% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FIS | HRTX | |
|---|---|---|
Market Cap | $21.24B | $84.50M |
Sector | Technology | Health |
52-Week High | $81.94 | $2.02 |
52-Week Low | $37.72 | $0.39 |
Enterprise Value | $41.63B | $182.40M |
Dividend Yield | 4.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.02, up 3.54% today, with a bearish technical signal but strong analyst support. The company shows improving fundamentals with Q1 2026 EPS beating expectations and a consensus price target of $52.57. Recent news highlights innovation in AI and cloud banking, though cash flow trends and debt levels warrant monitoring.
The outlook is cautiously optimistic with potential upside from earnings growth and strategic initiatives, balanced by risks from competitive pressures and financial leverage. Investor sentiment is positive driven by analyst buy ratings and recent business wins, but volatility may persist near-term.
HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.
The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
